DOP2018000102A - Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih - Google Patents
Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vihInfo
- Publication number
- DOP2018000102A DOP2018000102A DO2018000102A DO2018000102A DOP2018000102A DO P2018000102 A DOP2018000102 A DO P2018000102A DO 2018000102 A DO2018000102 A DO 2018000102A DO 2018000102 A DO2018000102 A DO 2018000102A DO P2018000102 A DOP2018000102 A DO P2018000102A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- trivalent
- prevention
- treatment
- proteins
- specific
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 5
- 108091008324 binding proteins Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 208000030507 AIDS Diseases 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente memoria se proporcionan que comprenden proteínas de unión triespecíficas y/o trivalentes que comprenden cuatro cadenas polipeptídicas que forman tres sitios de unión a antígeno que se unen específicamente a una o más proteínas diana del VIH o uno o más receptores de células T, en donde un primer par de polipéptidos que forman la proteína de unión posee dominios variables duales que tienen una orientación cruzada y en donde un segundo par de polipéptidos que forman la proteína de unión posee un solo dominio variable. También se proporcionan en la presente memoria métodos para preparar proteínas de unión triespecíficas y/o trivalentes y usos de tales proteínas de unión para el tratamiento y/o la prevención de VIH/SIDA.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562246113P | 2015-10-25 | 2015-10-25 | |
EP16305211 | 2016-02-24 | ||
US201662322029P | 2016-04-13 | 2016-04-13 | |
US201662331169P | 2016-05-03 | 2016-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2018000102A true DOP2018000102A (es) | 2018-11-30 |
Family
ID=55588187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2018000102A DOP2018000102A (es) | 2015-10-25 | 2018-04-20 | Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih |
Country Status (31)
Country | Link |
---|---|
US (3) | US20190054182A1 (es) |
EP (2) | EP3819310A1 (es) |
JP (3) | JP7169190B2 (es) |
KR (1) | KR20180063336A (es) |
CN (4) | CN116789841A (es) |
AR (1) | AR106466A1 (es) |
AU (2) | AU2016347058B2 (es) |
BR (1) | BR112018008011A2 (es) |
CA (1) | CA3002664A1 (es) |
CL (1) | CL2018001065A1 (es) |
CO (1) | CO2018005337A2 (es) |
CR (1) | CR20180288A (es) |
DO (1) | DOP2018000102A (es) |
EA (1) | EA201891028A1 (es) |
ES (1) | ES2894304T3 (es) |
HK (1) | HK1253385A1 (es) |
HR (1) | HRP20211528T1 (es) |
HU (1) | HUE056608T2 (es) |
IL (2) | IL301140A (es) |
MA (1) | MA42641A1 (es) |
MX (2) | MX2018005048A (es) |
MY (1) | MY192278A (es) |
PE (1) | PE20181167A1 (es) |
PH (1) | PH12018500873A1 (es) |
PL (1) | PL3365366T3 (es) |
RS (1) | RS62437B1 (es) |
SG (1) | SG11201803324VA (es) |
SI (1) | SI3365366T1 (es) |
TW (2) | TW202219064A (es) |
UY (1) | UY36965A (es) |
WO (1) | WO2017074878A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
CN106459186B (zh) * | 2014-02-28 | 2021-02-02 | 美国卫生和人力服务部 | 针对hiv-1 v1v2 env区域的广谱中和性单克隆抗体 |
CN116789841A (zh) | 2015-10-25 | 2023-09-22 | 赛诺菲 | 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白 |
EP3371214A1 (en) * | 2015-11-03 | 2018-09-12 | THE UNITED STATES OF AMERICA, represented by the S | Neutralizing antibodies to hiv-1 gp41 and their use |
RS64771B1 (sr) | 2016-04-13 | 2023-11-30 | Sanofi Sa | Trispecifični i/ili trovalentni vezujući proteini |
CR20180539A (es) | 2016-04-13 | 2019-02-15 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
JP7304288B2 (ja) | 2017-02-17 | 2023-07-06 | サノフイ | ジストログリカンおよびラミニン2に対する特異性を有する多特異性結合性分子 |
KR102324568B1 (ko) * | 2017-06-21 | 2021-11-10 | 길리애드 사이언시즈, 인코포레이티드 | HIV gp120 및 CD3을 표적화하는 다중특이적 항체 |
US11186649B2 (en) * | 2017-10-10 | 2021-11-30 | Sanofi | Anti-CD38 antibodies and methods of use |
JP7345861B2 (ja) * | 2017-12-21 | 2023-09-19 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 二重特異性hiv-1中和抗体 |
CA3088107A1 (en) | 2018-01-12 | 2019-07-18 | Genzyme Corporation | Methods for the quantitation of polypeptides |
US11845788B2 (en) | 2018-05-22 | 2023-12-19 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (HIV) |
AU2019357467A1 (en) | 2018-10-09 | 2021-05-27 | Sanofi | Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection |
US20220025021A1 (en) * | 2018-11-21 | 2022-01-27 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
TW202104274A (zh) | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療hiv感染之三特異性及/或三價結合蛋白 |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
WO2020210392A1 (en) | 2019-04-09 | 2020-10-15 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
US20210123926A1 (en) | 2019-10-25 | 2021-04-29 | Sanofi | Methods for analyzing chain mispairing in multispecific binding proteins |
US20230203466A1 (en) * | 2020-04-03 | 2023-06-29 | Medgenome Inc. | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment |
CR20230101A (es) * | 2020-08-25 | 2023-04-28 | Gilead Sciences Inc | Moléculas de unión a antígeno multi- específicas contra el vih y métodos de uso |
US20240059798A1 (en) * | 2021-12-21 | 2024-02-22 | Modex Therapeutics, Inc. | Conditionally activated antigen binding polypeptide complexes and methods of use thereof |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE108068T1 (de) | 1987-09-23 | 1994-07-15 | Bristol Myers Squibb Co | Antikörper-heterokonjugate zur töting von hiv- infizierten zellen. |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
KR100927261B1 (ko) | 2001-01-17 | 2009-11-18 | 트루비온 파마슈티칼스, 인코포레이티드 | 결합 도메인-면역글로불린 융합 단백질 |
CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
AU2004252170B2 (en) | 2003-06-27 | 2011-01-27 | Biogen Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
JP2011523853A (ja) | 2008-06-03 | 2011-08-25 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリン及びその使用 |
WO2011038290A2 (en) | 2009-09-25 | 2011-03-31 | The U. S. A., As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
LT2580243T (lt) | 2010-06-09 | 2020-01-27 | Genmab A/S | Antikūnai prieš žmogaus cd38 |
EP2638072A4 (en) | 2010-11-12 | 2014-05-07 | Univ Rockefeller | FUSION PROTEINS FOR HIV THERAPY |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
TWI588156B (zh) | 2011-03-28 | 2017-06-21 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
CN103842383B (zh) | 2011-05-16 | 2017-11-03 | 健能隆医药技术(上海)有限公司 | 多特异性fab融合蛋白及其使用方法 |
DK2710033T3 (da) * | 2011-05-17 | 2021-03-08 | Univ Rockefeller | Human immundefektvirus-neutraliserende antistoffer og fremgangsmåder til anvendelse deraf |
EP2776463B1 (en) | 2011-11-07 | 2017-09-20 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing gp41 antibodies and their use |
CA2854806A1 (en) * | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
US9695230B2 (en) | 2011-12-08 | 2017-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein |
WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
EP3401337A1 (en) * | 2012-09-25 | 2018-11-14 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
EP2928924A4 (en) | 2012-12-04 | 2016-07-13 | Univ Maryland | HIV-1 ENV BINDING ANTIBODIES, FUSION PROTEINS AND METHODS OF USE |
WO2014093894A2 (en) | 2012-12-13 | 2014-06-19 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
US20140213772A1 (en) | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
NZ708182A (en) * | 2013-02-26 | 2019-08-30 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
RU2015143833A (ru) | 2013-03-15 | 2017-04-21 | Эббви Инк. | СВЯЗЫВАЮЩИЕ БЕЛКИ С ДВОЙНОЙ СПЕЦИФИЧНОСТЬЮ, НАПРАВЛЕННЫЕ ПРОТИВ TNFα |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
US9951118B2 (en) | 2013-08-02 | 2018-04-24 | The Regents Of The University Of California | Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors |
CN110627907B (zh) | 2013-11-04 | 2024-03-29 | 艾科诺斯科技股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
SG11201607983YA (en) | 2014-03-28 | 2016-10-28 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
CN106687584B (zh) | 2014-09-04 | 2021-08-13 | 干细胞技术公司 | 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物 |
CN107428835B (zh) | 2015-01-23 | 2021-11-26 | 赛诺菲 | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 |
CA2986237A1 (en) | 2015-05-20 | 2016-11-24 | Quantum-Si Incorporated | Method of determining the sequence of a nucleic acid using time resolved luminescence |
WO2016196740A1 (en) | 2015-06-02 | 2016-12-08 | The Rockefeller University | Tri-specific antibodies for hiv therapy |
WO2017053556A1 (en) | 2015-09-22 | 2017-03-30 | The Trustees Of The University Of Pennsylvania | Method of redirecting t cells to treat hiv infection |
CN116789841A (zh) | 2015-10-25 | 2023-09-22 | 赛诺菲 | 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白 |
CN105837688B (zh) | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因,免疫毒素及其编码基因、制备方法、表达载体、应用,及宿主细胞 |
SG10202108793TA (en) | 2015-12-15 | 2021-09-29 | Gilead Sciences Inc | Human immunodeficiency virus neutralizing antibodies |
RS64771B1 (sr) | 2016-04-13 | 2023-11-30 | Sanofi Sa | Trispecifični i/ili trovalentni vezujući proteini |
CR20180539A (es) | 2016-04-13 | 2019-02-15 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes |
WO2018120842A1 (zh) | 2016-12-30 | 2018-07-05 | 上海欣百诺生物科技有限公司 | 一种双功能分子及其应用 |
JP7304288B2 (ja) | 2017-02-17 | 2023-07-06 | サノフイ | ジストログリカンおよびラミニン2に対する特異性を有する多特異性結合性分子 |
WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
US11845787B2 (en) | 2017-03-27 | 2023-12-19 | The Wistar Institute Of Anatomy And Biology | DNA antibody constructs for use against HIV |
US11186649B2 (en) | 2017-10-10 | 2021-11-30 | Sanofi | Anti-CD38 antibodies and methods of use |
AU2019357467A1 (en) | 2018-10-09 | 2021-05-27 | Sanofi | Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
-
2016
- 2016-10-24 CN CN202310186776.6A patent/CN116789841A/zh active Pending
- 2016-10-24 CA CA3002664A patent/CA3002664A1/en active Pending
- 2016-10-24 CN CN201680075852.4A patent/CN109311966B/zh active Active
- 2016-10-24 JP JP2018521308A patent/JP7169190B2/ja active Active
- 2016-10-24 BR BR112018008011A patent/BR112018008011A2/pt active Search and Examination
- 2016-10-24 SI SI201631358T patent/SI3365366T1/sl unknown
- 2016-10-24 MA MA42641A patent/MA42641A1/fr unknown
- 2016-10-24 ES ES16794472T patent/ES2894304T3/es active Active
- 2016-10-24 EP EP20197556.2A patent/EP3819310A1/en active Pending
- 2016-10-24 PL PL16794472T patent/PL3365366T3/pl unknown
- 2016-10-24 RS RS20211266A patent/RS62437B1/sr unknown
- 2016-10-24 HR HRP20211528TT patent/HRP20211528T1/hr unknown
- 2016-10-24 US US15/770,471 patent/US20190054182A1/en not_active Abandoned
- 2016-10-24 AU AU2016347058A patent/AU2016347058B2/en active Active
- 2016-10-24 WO PCT/US2016/058540 patent/WO2017074878A1/en active Application Filing
- 2016-10-24 HU HUE16794472A patent/HUE056608T2/hu unknown
- 2016-10-24 MX MX2018005048A patent/MX2018005048A/es unknown
- 2016-10-24 CR CR20180288A patent/CR20180288A/es unknown
- 2016-10-24 KR KR1020187014534A patent/KR20180063336A/ko active IP Right Grant
- 2016-10-24 PE PE2018000603A patent/PE20181167A1/es unknown
- 2016-10-24 MY MYPI2018701634A patent/MY192278A/en unknown
- 2016-10-24 SG SG11201803324VA patent/SG11201803324VA/en unknown
- 2016-10-24 CN CN202310185803.8A patent/CN117069855A/zh active Pending
- 2016-10-24 EA EA201891028A patent/EA201891028A1/ru unknown
- 2016-10-24 IL IL301140A patent/IL301140A/en unknown
- 2016-10-24 CN CN202310147287.XA patent/CN116675776A/zh active Pending
- 2016-10-24 EP EP16794472.7A patent/EP3365366B1/en active Active
- 2016-10-25 AR ARP160103249A patent/AR106466A1/es unknown
- 2016-10-25 TW TW110126977A patent/TW202219064A/zh unknown
- 2016-10-25 UY UY0001036965A patent/UY36965A/es not_active Application Discontinuation
- 2016-10-25 TW TW105134405A patent/TWI750139B/zh active
-
2018
- 2018-04-20 DO DO2018000102A patent/DOP2018000102A/es unknown
- 2018-04-22 IL IL258822A patent/IL258822B2/en unknown
- 2018-04-23 PH PH12018500873A patent/PH12018500873A1/en unknown
- 2018-04-23 CL CL2018001065A patent/CL2018001065A1/es unknown
- 2018-04-24 MX MX2022014631A patent/MX2022014631A/es unknown
- 2018-05-22 CO CONC2018/0005337A patent/CO2018005337A2/es unknown
- 2018-10-04 HK HK18112682.8A patent/HK1253385A1/zh unknown
-
2019
- 2019-10-21 US US16/659,426 patent/US11129905B2/en active Active
-
2021
- 2021-02-04 JP JP2021016190A patent/JP7328267B2/ja active Active
- 2021-08-17 US US17/404,908 patent/US11779651B2/en active Active
-
2023
- 2023-04-06 JP JP2023061823A patent/JP2023085476A/ja active Pending
-
2024
- 2024-01-22 AU AU2024200395A patent/AU2024200395A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2018000102A (es) | Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih | |
CO2018012107A2 (es) | Proteínas de unión triespecíficas y/o trivalentes | |
CY1124252T1 (el) | Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου | |
EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
BR112018067458A2 (pt) | anticorpos para tigit | |
BR112018073761A2 (pt) | proteínas de ligação ao cd3 de fragmento variável de cadeia única | |
BR112018012707A2 (pt) | inibidores da interação de menin-mll | |
BR112017025191A2 (pt) | anticorpos contra ox40 e uso dos mesmos | |
EA201692539A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
WO2015197598A3 (en) | Multispecific antigen binding proteins | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
BR112017009764A2 (pt) | anticorpos biespecíficos e métodos de uso em oftalmologia | |
CO2017011583A2 (es) | Polipéptidos dirigidos a la fusión de vih | |
UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
MX2023004804A (es) | Proteinas de union triespecificas y/o trivalentes. | |
ECSP18039758A (es) | Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih | |
AR118602A1 (es) | Proteínas de unión triespecíficas y/o trivalentes para el tratamiento de la infección por vih | |
EA201692564A1 (ru) | Комбинированная терапия | |
AR113069A1 (es) | VARIANTES DE ANTICUERPOS QUE SE UNEN A TNFa | |
EA201892085A1 (ru) | Новые белки, полученные из альфа-1-микроглобулина, и их применение | |
ECSP18084491A (es) | Proteínas de unión triespecíficas y/o trivalentes | |
EA202191078A2 (ru) | Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv | |
AR108210A1 (es) | Proteínas de unión triespecíficas y/o trivalentes |